文献速递免疫规划妇幼与学校卫生传染病防控与疫情报告

常规单克隆抗体预防与母体免疫对意大利伦巴第地区2024/25季节呼吸道合胞病毒住院的影响

Impact of routine prophylaxis with monoclonal antibodies and maternal immunisation to prevent respiratory syncytial virus hospitalisations, Lombardy region, Italy, 2024/25 season.
PubMed 文献 · Euro Surveill · 2025-01-01

该研究使用催化模型,基于新冠疫情前(2020年前)及疫情后(至2022年)数据,评估2024/25季节意大利伦巴第地区婴儿尼塞韦单抗接种与孕妇RSVpreF疫苗接种对呼吸道合胞病毒下呼吸道感染住院的潜在影响。结果显示,80%新生儿接种尼塞韦单抗可避免总人群50.2%(95%CI:43.5-55.8)的住院,65%孕妇接种可避免30.5%(95%CI:19.6-39.7)的住院。

要点

  • 80%新生儿接种尼塞韦单抗估计可避免总人群50.2%(95%CI:43.5-55.8)的RSV住院。
  • 孕妇接种率65%时,母体免疫估计可避免30.5%(95%CI:19.6-39.7)的住院。
  • 孕妇接种率12%(流感疫苗覆盖率水平)时,母体免疫可避免的住院不足8%。

核心结论

  • 常规给婴儿接种尼塞韦单抗显示出降低RSV相关住院的明确潜力。
  • 母体免疫可有助于在高风险人群中实现高保护。

研究设计与样本

  • 使用由新冠疫情前(2020年前)及疫情后(至2022年)数据构建的催化模型,量化季节性尼塞韦单抗婴儿接种和RSVpreF孕妇接种可避免的病例数和住院数,并考虑疫情期间RSV传播减少导致的易感性变化。

主要发现

  • 婴儿尼塞韦单抗接种率80%时,估计可避免总人群50.2%(95%CI:43.5-55.8)的住院。
  • 接种率接近儿童疫苗水平(95%)时,可额外平均减少18%的住院。
  • 孕妇接种率65%时,估计可避免30.5%(95%CI:19.6-39.7)的住院。
  • 孕妇接种率12%时,母体免疫可避免的住院不足8%。

关键数值与推荐

  • 婴儿尼塞韦单抗接种率80%时,估计避免总人群50.2%(95%CI:43.5-55.8)的住院。
  • 接种率95%时,可额外平均减少18%的住院。
  • 孕妇接种率65%时,估计避免30.5%(95%CI:19.6-39.7)的住院。
  • 孕妇接种率12%时,可避免的住院不足8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundRespiratory syncytial virus (RSV) is a leading cause of hospitalisation in children worldwide. Recent regulatory approval of monoclonal antibody (mAb) nirsevimab for infants and the RSVpreF vaccine for pregnant women offers promising approaches to mitigate RSV-associated morbidity.AimTo evaluate potential impacts of routine prophylactic campaigns (mAbs targeting infants or maternal vaccination) introduced in the 2024/25 season on hospitalisations from RSV lower respiratory tract infections in Lombardy, Italy.MethodsWe used a catalytic model informed by data from pre-COVID-19 pandemic (before 2020) and post-pandemic periods (until 2022) to quantify the number of cases and hospitalisations that could be averted by seasonal nirsevimab administration to infants and RSVpreF maternal vaccination, considering changes in susceptibility caused by reduced RSV circulation during the pandemic.ResultsAs a marked proportion of RSV hospitalisations occurs in infants aged ≤ 1 year, seasonal mAb administration to 80% of newborns (uptake levels observed in Spain) was estimated to avert 50.2% (95% CI: 43.5-55.8) of hospitalisations in the total population. Coverage levels close to those observed for childhood vaccines (95%) could result in an additional average 18% reduction in hospitalisations. Vaccination of 65% of pregnant women, resembling the diphtheria-tetanus-pertussis vaccine coverage in Lombardy for this population, was estimated to avert 30.5% (95% CI: 19.6-39.7) of hospitalisations. At influenza vaccine coverage (12%), less than 8% of hospitalisations could be averted by maternal immunisation.ConclusionRoutine nirsevimab administration to infants demonstrates clear potential to reduce RSV-associated hospitalisations. Maternal immunisation can help in achieving high protection in at-risk populations.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Menegale F, Vezzosi L, Tirani M, et al. Impact of routine prophylaxis with monoclonal antibodies and maternal immunisation to prevent respiratory syncytial virus hospitalisations, Lombardy region, Italy, 2024/25 season. Euro Surveill. 2025. PMID: 40211969. doi:10.2807/1560-7917.ES.2025.30.14.2400637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。